Full-Time

Associate Director

Clinical Supply Chain

Confirmed live in the last 24 hours

Revolution Medicines

Revolution Medicines

201-500 employees

Develops targeted therapies for RAS-driven cancers

Biotechnology
Healthcare

Compensation Overview

$160k - $200kAnnually

Senior

San Carlos, CA, USA

Hybrid position requiring in-office presence.

Category
Inventory Management
Supply Chain Management
Operations & Logistics
Required Skills
Inventory Management
Requirements
  • B.S. or M.S. in scientific fields with 8+ years of experience in clinical supply chain and logistics.
  • Working knowledge of import and export laws and processes.
  • Working knowledge of pharmaceutical drug product development and manufacturing.
  • Solid organizational and time management skills.
  • Effective, open, and transparent communication skills (verbal and written).
  • Capable of working on multiple projects/tasks and able to meet timelines.
  • Team-oriented, progressive thinker who enjoys participating in an innovative and creative work environment.
Responsibilities
  • Serve as the clinical supply lead for assigned program(s) and develop/manage the clinical supply plan.
  • Plan and deliver on-time, compliant clinical supply per the clinical development plan.
  • Collaborate with cross-functional teams (i.e. Clinical Operations, QA, PDM, and Regulatory) to ensure continued advancement of the clinical programs.
  • Lead and manage clinical supply and logistics activities, including but not limited to: demand forecasting and supply planning, IRT start-up and maintenance, label generation and approval, packaging and labeling operations, release and distribution, expiry extension, cold chain management, and inventory management.
  • Author, review, and/or approve related clinical and technical documents, including but not limited to: clinical label text, clinical/master batch record, clinical trial protocol, pharmacy manual, IND, IMPD, and NDA.
  • Support vendor identification, selection, onboarding, and management for combo agent/comparator sourcing and secondary packaging and distribution.
  • Conduct necessary training and develop/improve required SOPs.

Revolution Medicines develops treatments specifically for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main product line includes RASON Inhibitors, designed to target and inhibit RAS proteins that contribute to cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses solely on RAS-driven cancers, allowing them to carve out a niche in the oncology market. Their goal is to transform cancer treatment by providing effective targeted therapies for patients suffering from these challenging conditions.

Company Stage

IPO

Total Funding

$219.8M

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

15%

1 year growth

42%

2 year growth

137%
Simplify Jobs

Simplify's Take

What believers are saying

  • The acquisition of EQRx is expected to add over $1 billion in net cash, significantly bolstering Revolution Medicines' financial position.
  • Successful public offerings and underwriters' full exercise of options have brought substantial capital, indicating strong investor confidence.
  • The company's innovative RASON Inhibitors and Tri Complex Inhibitor platform have the potential to revolutionize treatment for RAS-driven cancers, offering significant clinical impact.

What critics are saying

  • The highly specialized focus on RAS-driven cancers may limit market size and revenue potential compared to broader oncology companies.
  • Integration challenges from the acquisition of EQRx could divert focus and resources, potentially impacting ongoing projects.

What makes Revolution Medicines unique

  • Revolution Medicines focuses exclusively on RAS-driven cancers, a niche but critical area in oncology, unlike broader-spectrum oncology companies.
  • Their Tri Complex Inhibitor platform allows for highly specialized treatments, setting them apart from competitors with more generalized approaches.
  • The company's revenue model, which includes licensing, co-development partnerships, and direct sales, provides multiple revenue streams, enhancing financial stability.

Help us improve and share your feedback! Did you find this helpful?